Dataset Information

Human colon aspirate proteins analyzed by LC-MSMS

ABSTRACT: Colonic aspirates were collected at diagnostic colonoscopy from inflammatory bowel disease (IBD) and control, treatment-naive children. The colonic mucosal-luminal interface (MLI) proteomes were analyzed for 18 control and 42 IBD patients by liquid-chromatography mass spectrometry.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Colon

SUBMITTER: Shelley Deeke

LAB HEAD: Daniel Figeys

PROVIDER: PXD006383 | Pride | 2018-03-19

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	IBD_Lavage_20140423_CD_Moderate_406_CoA_Ascending_Colon_Female_CO_F1_and_F5.raw	Raw
	IBD_Lavage_20140423_CD_Moderate_406_CoA_Ascending_Colon_Female_CO_F2_140507231117.raw	Raw
	IBD_Lavage_20140423_CD_Moderate_406_CoA_Ascending_Colon_Female_CO_F3.raw	Raw
	IBD_Lavage_20140423_CD_Moderate_406_CoA_Ascending_Colon_Female_CO_F4.raw	Raw
	IBD_Lavage_20140423_Control_397_CoN_Ascending_Colon_Female_CO_F1_and_F5_140430003205.raw	Raw

Items per page:

1 - 5 of 449

Publications

Mucosal-luminal interface proteomics reveals biomarkers of pediatric inflammatory bowel disease-associated colitis.

Deeke Shelley A SA Starr Amanda E AE Ning Zhibin Z Ahmadi Sara S Zhang Xu X Mayne Janice J Chiang Cheng-Kang CK Singleton Ruth R Benchimol Eric I EI Mack David R DR Stintzi Alain A Figeys Daniel D

The American journal of gastroenterology 20180312 5

<h4>Objective</h4>Improved biomarkers are an unmet clinical need for suspected inflammatory bowel disease (IBD). Need is greatest for children, since current biomarkers suffers from low specificity, particularly in this population; thus, invasive testing methods, with the accompanying risk of complications, are necessary. Additionally, current biomarkers do not delineate disease extent assessment for ulcerative colitis (UC), a factor involved in therapeutic decisions.<h4>Methods</h4>Intestinal m ...[more]

PMID: 29531307

Similar Datasets

Project description:Colorectal cancer often arises from adenomatous polyps. Polyps can grow and progress to cancer, but may also remain static in size, regress, or resolve. Prediciting which progress to cancer and which remain benign is difficult. We developed a long-lived murine model of colorectal cancer with tumors that can be followed by colonoscopy. Our aim was to assess whether these tumors have similar growth patterns and histologic fates to human colorectal polyps to identify features to aid in risk stratification of colonic tumors. Long-lived Apcin/+ mice were treated with 4% dextran sodium sulfate to promote colonic tumorigenesis. Tumor growth patterns were characterized by serial colonoscopy, and pathology was determined. Serial biopsies of tumors were obtained for immunohistochemistry and gene expression profiling by microarray analysis with Affymetrix Whole Genome array. Tumors (n=424) grew, remained static, regressed, or resolved over time with different relative frequencies. Newly developed tumors demonstrated dynamic growth patterns with higher rates of growth and resolution, while more established tumors tended to remain static in size. Colonic tumors were hyperplastic lesions (3%), adenomas (73%), intramucosal carcinomas (20%), or adenocarcinomas (3%). Differentially expressed genes between adenomas and intramucosal carcinomas were identified. We did not identify differentially expressed genes between early and late biopsies from the same tumor. This novel murine model of intestinal tumorigenesis develops colonic tumors that can be monitored by serial colonoscopy, mirror growth patterns seen in human colorectal polyps, and progress to colorectal cancer. Further characterization of cellular and molecular features are needed to determine which features can be used to risk-stratify polyps for progress to colorectal cancer and potentially guide prevention strategies. F1 (SWR x C57BL/6) Apcin/+ mice who had been given two treatments of 4% dextran sodium sulfate in drinking water at weaning underwent colonoscopy around 80 days of age. Those with distal colonic tumors amenable to biopsy had two biopsies taken at that time. Tumors were monitored by colonoscopy every 14 days. Every 28 days, two additional biopsies were taken of each tumor. This protocol was repeated until mice were moribund. Six tumors were removed after sacrifice. The earliest and latest biopsies of each tumor were selected for RNA extraction and Affymetrix hybridization.